

Martin Hutchings

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9035372/martin-hutchings-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

6,800
citations

35
h-index

81
g-index

164
ext. papers

8,292
ext. citations

3.7
avg, IF

5.45
L-index

#	Paper	IF	Citations
151	Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts). <i>Blood</i> , 2021 , 138, 2478-2478	2.2	2
150	Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL). <i>Blood</i> , 2021 , 138, 128-128	2.2	1
149	Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2021 , 138, 525-525	2.2	2
148	Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial. <i>Blood</i> , 2021 , 138, 2627-2627	2.2	0
147	Glofitamab Plus R-CHOP Induces High Response Rates with Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results from a Dose-Escalation and Safety Run-in Phase Ib Study. <i>Blood</i> , 2021 , 138, 2479-2479	2.2	2
146	Axillary lymph nodes on PET in Hodgkin lymphoma after COVID-19 vaccination.. <i>EJHaem</i> , 2021 , 2, 885-886	0.9	0
145	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , 2021 , 5, e510	0.3	2
144	Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7519-7519	2.2	0
143	Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 7518-7518	2.2	3
142	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. <i>Blood Advances</i> , 2021 , 5, 2375-2384	7.8	9
141	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1959-1970	2.2	57
140	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3463-3472	2.2	0
139	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e410-e421	14.6	20
138	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. <i>Cancer Reports</i> , 2021 , e1524	1.5	
137	Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2021 , 106, 1129-1137	6.6	19
136	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. <i>Hematological Oncology</i> , 2021 , 39, 185-195	1.3	3
135	Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. <i>European Journal of Haematology</i> , 2021 , 106, 697-707	3.8	0

134	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 4762-4770	7.8	3
133	Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. <i>Lancet, The</i> , 2021 , 398, 1157-1169	4.0	22
132	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. <i>BMC Cancer</i> , 2020 , 20, 1202	4.8	1
131	Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma. <i>Radiology: Artificial Intelligence</i> , 2020 , 2, e200016	8.7	11
130	Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible. <i>Blood</i> , 2020 , 136, 15-15	2.2	3
129	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. <i>Blood</i> , 2020 , 136, 36-36 ^{2.2}	2.2	3
128	Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data. <i>Blood</i> , 2020 , 136, 45-46	2.2	29
127	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. <i>Blood</i> , 2020 , 136, 16-18	2.2	1
126	Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma. <i>Blood</i> , 2020 , 136, 46-48	2.2	25
125	Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma. <i>Blood</i> , 2020 , 136, 16-17	2.2	2
124	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , 2020 , 136, 26-28	2.2	3
123	Epcoritamab (GEN3013; DuoBody-CD3 α D20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8009-8009	2.2	16
122	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2020 , 113-143	0	
121	Comparison of 11 automated PET segmentation methods in lymphoma. <i>Physics in Medicine and Biology</i> , 2020 , 65, 235019	3.8	7
120	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. <i>Cancer Medicine</i> , 2020 , 9, 6565-6575	4.8	11
119	Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. <i>Journal of Nuclear Cardiology</i> , 2020 , 27, 1698-1707	2.1	6
118	I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. <i>Journal of Nuclear Cardiology</i> , 2020 , 27, 931-939	2.1	2
117	Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. <i>Cancer Medicine</i> , 2020 , 9, 4395-4404	4.8	7

116	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020 , 135, 735-742	2.2	54
115	First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody [®] -CD3 ⁺ CD20) in B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2019 , 134, 758-758	2.2	16
114	The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium. <i>Blood</i> , 2019 , 134, 487-487	2.2	4
113	Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial. <i>Blood</i> , 2019 , 134, 1584-1584	2.2	19
112	CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 2871-2871	2.2	15
111	Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial. <i>Blood</i> , 2019 , 134, 2816-2816 ⁷	2.2	7
110	Fertility Rates in Young Hodgkin Lymphoma Survivors: A Danish Nationwide Cohort Study of 769 Patients. <i>Blood</i> , 2019 , 134, 2841-2841	2.2	
109	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. <i>Blood</i> , 2019 , 134, 4026-4026	2.2	
108	PET-adapted treatment of Hodgkin lymphoma. <i>Blood</i> , 2019 , 134, 1200-1201	2.2	3
107	Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study. <i>Haematologica</i> , 2019 , 104, e151-e153	6.6	17
106	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018 , 93, 57-68	7.5	37
105	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018 , 29, 544-562	10.3	42
104	Can we improve on ibrutinib in mantle cell lymphoma?. <i>Lancet Haematology,the</i> , 2018 , 5, e98-e99	14.6	
103	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018 , 131, 1456-1463	2.2	77
102	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Haematology,the</i> , 2018 , 5, e109-e116	14.6	76
101	I-MIBG imaging for detection of anthracycline-induced cardiomyopathy. <i>Clinical Physiology and Functional Imaging</i> , 2018 , 38, 176-185	2.4	5
100	PET/CT for Staging; Past, Present, and Future. <i>Seminars in Nuclear Medicine</i> , 2018 , 48, 4-16	5.4	31
99	Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 589-595	8.9	31

98	ESMO Consensus Conference on malignant lymphoma: management of ultra-high-risk patients. <i>Annals of Oncology</i> , 2018 , 29, 1687-1700	10.3	9
97	CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I First in Human Trial. <i>Blood</i> , 2018 , 132, 226-226	2.2	18
96	Combining Brentuximab Vedotin with DHAP as Salvage Treatment in Relapsed/Refractory Hodgkin Lymphoma: The Phase II HOVON/LLPC Transplant BRaVE study. <i>Blood</i> , 2018 , 132, 2923-2923	2.2	11
95	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018 , 132, 391-391	2.2	25
94	Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018 , 132, 2904-2904	2.2	4
93	B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisolone) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSg) and the Nordic Lymphoma Group (NLG). <i>Blood</i> , 2018 , 132, 926-926	2.2	7
92	Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin lymphoma (HL): Impact of cycle 2 PET result on modified progression-free survival (mPFS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7539-7539	2.2	5
91	A small change makes a big difference in Hodgkin lymphoma. <i>Blood</i> , 2018 , 132, 2214-2215	2.2	1
90	Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography. <i>Cancer Journal (Sudbury, Mass)</i> , 2018 , 24, 215-222	2.2	2
89	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv19-iv29	10.3	142
88	Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group. <i>Acta Oncologica</i> , 2017 , 56, 608-613	3.2	9
87	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , 2017 , 75, 195-203	7.5	35
86	Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. <i>Annals of Oncology</i> , 2017 , 28, 1352-1358	10.3	52
85	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , 2017 , 28, 1436-1447	10.3	148
84	Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1786-1794	2.2	264
83	Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up. <i>British Journal of Haematology</i> , 2017 , 176, 65-75	4.5	16
82	Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study. <i>British Journal of Haematology</i> , 2017 , 176, 671-673	4.5	6
81	PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup. <i>Blood</i> , 2017 , 130, 736-736	2.2	8

80	Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS7575-TPS7575	2.2	3
79	Concomitant semi-quantitative and visual analysis improves the predictive value on treatment outcome of interim 18F-Fluorodeoxyglucose / Positron Emission Tomography in advanced Hodgkin lymphoma. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 ,	1.4	2
78	Reply to H.J adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?". <i>American Journal of Hematology</i> , 2016 , 91, E2-3	7.1	
77	The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. <i>Annals of Oncology</i> , 2016 , 27, 1095-1099	10.3	28
76	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. <i>Blood</i> , 2016 , 128, 148-148	12.2	12
75	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. <i>Blood</i> , 2016 , 128, 184-184	2.2	1
74	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1874-1874	2.2	2
73	PET/CT for HL Staging 2016 , 1-13		
72	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. <i>British Journal of Haematology</i> , 2016 , 173, 236-44	4.5	24
71	Clinical presentation and staging of Hodgkin lymphoma. <i>Seminars in Hematology</i> , 2016 , 53, 148-54	4	13
70	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , 2016 , 175, 876-883	4.5	18
69	Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. <i>Cancer Treatment and Research</i> , 2015 , 165, 125-46	3.5	8
68	Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Cancer Treatment Communications</i> , 2015 , 4, S1-S11		0
67	A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. <i>British Journal of Haematology</i> , 2015 , 169, 435-44	4.5	24
66	Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. <i>American Journal of Hematology</i> , 2015 , 90, 1041-6	7.1	50
65	Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. <i>Oncologist</i> , 2015 , 20, 890-5	5.7	4
64	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3993-8	2.2	62
63	FDG-PET for the early treatment monitoring, for final response and follow-up evaluation in lymphoma. <i>Clinical and Translational Imaging</i> , 2015 , 3, 271-281	2	1

62	New clues to the prognostic challenge of Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 277-8	1.9	2
61	Targeted immunotherapy in Hodgkin lymphoma. <i>Blood</i> , 2015 , 125, 3967-8	2.2	2
60	Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients. <i>American Journal of Hematology</i> , 2015 , 90, 975-80	7.1	40
59	Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1221-3	2.2	3
58	Reply to G. Keramida et al. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4121-2	2.2	1
57	(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2005-12	1.9	20
56	Risk Factors and a Prognostic Score for Progression Free Survival after Treatment with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory Hodgkin Lymphoma (rrHL). <i>Blood</i> , 2015 , 126, 1978-1978	2.2	4
55	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2015 , 126, 3905-3905	2.2	1
54	Functional Imaging in Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2015 , 107-130	0	2
53	Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014 , 89, 575-80	7.1	40
52	FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 87-103	3.1	8
51	In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2705-11	2.2	67
50	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii70-5	10.3	127
49	Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2349-55	1.9	20
48	Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma. <i>PET Clinics</i> , 2014 , 9, 443-55, vi	2.2	3
47	Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3048-58	2.2	927
46	Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1188-94	2.2	272
45	Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1563-9	1.9	5

44	Suspected Richter transformation: positron emission tomography/computed tomography tells us who should have a biopsy and where. <i>Leukemia and Lymphoma</i> , 2014 , 55, 233-4	1.9	6
43	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , 2014 , 99, 1107-13	6.6	179
42	The Complementary Prognostic Role of Baseline and Interim PET in Predicting Treatment Outcome in Advanced-Stage Hodgkin Lymphoma. <i>Blood</i> , 2014 , 124, 4405-4405	2.2	5
41	Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era. <i>Blood</i> , 2014 , 124, 2960-2960	2.2	
40	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. <i>Blood</i> , 2014 , 124, 1630-1630	2.2	1
39	Cancer mortality does not differ between migrants and Danish-born patients. <i>Danish Medical Journal</i> , 2014 , 61, A4848	3.8	3
38	International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 683-90	8.9	224
37	Interim FDG PET/CT to predict progression-free survival (PFS) better than clinical and baseline metabolic measurements in Hodgkin lymphoma (cHL).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 8555-8555	2.2	2
36	The International Prognostic Index Predicts Outcome In Patients With Untreated Nodal Peripheral T-Cell Lymphomas Staged With PET/CT. <i>Blood</i> , 2013 , 122, 5077-5077	2.2	
35	Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4508-14	2.2	191
34	The role of bone marrow biopsy in Hodgkin lymphoma staging: "to be, or not to be, that is the question"?. <i>Leukemia and Lymphoma</i> , 2012 , 53, 523-4	1.9	2
33	FDG-PET/CT based response-adapted treatment. <i>Cancer Imaging</i> , 2012 , 12, 324-35	5.6	16
32	When and how to perform surveillance imaging in patients with lymphoma, and is it worth it?. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1015-6	1.9	1
31	Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. <i>Haematologica</i> , 2012 , 97, 931-6	6.6	61
30	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 322-7	3.1	11
29	How does PET/CT help in selecting therapy for patients with Hodgkin lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 322-327	3.1	19
28	Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma. <i>Blood</i> , 2012 , 120, 549-549	2.2	17
27	Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.. <i>Blood</i> , 2012 , 120, 2637-2637	2.2	

26	Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients. <i>Blood</i> , 2012 , 120, 1532-1532	2.2	
25	The Role of Imaging in Radiotherapy for Hodgkin Lymphoma 2011 , 81-89		1
24	Routine follow-up scanning of patients with lymphoma: who, when, how, and why?. <i>Leukemia and Lymphoma</i> , 2011 , 52, 552-3	1.9	2
23	Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients?. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1615-6	1.9	6
22	Functional Imaging 2011 , 77-95		
21	Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging. <i>Blood</i> , 2011 , 118, 2627-2627	2.2	
20	Correlation of FDG-PET results after one cycle and after two cycles of chemotherapy in Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2010 , 28, 8061-8061	2.2	2
19	PET imaging in lymphoma. <i>Expert Review of Hematology</i> , 2009 , 2, 261-76	2.8	3
18	PET/CT for therapy response assessment in lymphoma. <i>Journal of Nuclear Medicine</i> , 2009 , 50 Suppl 1, 21S-30S	8.9	158
17	Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma: a systematic review. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1906-14	2.2	214
16	PET/CT in the management of haematological malignancies. <i>European Journal of Haematology</i> , 2008 , 80, 369-80	3.8	36
15	Treatment of Hodgkin lymphoma: the past, present, and future. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 543-56		75
14	Early interim PET scan in Hodgkin lymphoma: where do we stand?. <i>Leukemia and Lymphoma</i> , 2008 , 49, 659-62	1.9	31
13	Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. <i>European Journal of Haematology</i> , 2007 , 78, 206-12	3.8	90
12	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3746-52	2.2	667
11	Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. <i>Hematological Oncology</i> , 2006 , 24, 146-50	1.3	71
10	FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. <i>Blood</i> , 2006 , 107, 52-9	2.2	592
9	Position emission tomography with or without computed tomography in the primary staging of Hodgkin lymphoma. <i>Haematologica</i> , 2006 , 91, 482-9	6.6	175

8	FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. <i>Annals of Oncology</i> , 2005 , 16, 1514-23	10.3	323
7	Volume of Abnormal Tumour Tissue on FDG-PET - a Predictor of Progression-Free Survival in Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 63, S45	4	3
6	Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. <i>Annals of Oncology</i> , 2005 , 16, 1160-8	10.3	267
5	Different Histopathological Subtypes of Hodgkin Lymphoma Have Significantly Different Levels of FDG Uptake.. <i>Blood</i> , 2005 , 106, 969-969	2.2	1
4	The prognostic value of interim positron emission tomography scans combined with immunohistochemical data in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2005 , 90, 1711-3	6.6	4
3	FDG-PET in the clinical management of Hodgkin lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2004 , 52, 19-32	7	46
2	Uptake of FDG in Lemierre® syndrome with normal leucocyte scintigraphy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003 , 30, 489	8.8	2
1	Renal ¹³¹ I-hippuran extraction in man: effects of dopamine. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 675-7	3.8	6